$Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience$

Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience

As an immunomodulatory drug, lenalidomide has been shown to have anti-lymphoma activity and is used in combination with several agents in the treatment of patients with relapsed/refractory disease. In this study, we aimed to evaluate the efficiency of lenalidomide in the treatment of B-cell NHL. Thi...

Full description

Bibliographic Details
Main Authors:	Mustafa Merter, Ayse Uysal
Format:	Article
Language:	English
Published:	Society of Turaz Bilim 2022-06-01
Series:	Medicine Science
Subjects:	b-cell lymphoma lenalidomide immunomodulatory drug relapsed/refractory disease
Online Access:	http://www.ejmanager.com/fulltextpdf.php?mno=12001

Similar Items

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study
by: Jingjing Ma, et al.
Published: (2022-07-01)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
by: Felipe de Arriba de la Fuente, et al.
Published: (2022-12-01)

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
by: Anna Furlan, et al.
Published: (2024-04-01)

Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
by: Ying Shang, et al.
Published: (2023-12-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma
by: Robin Noel, et al.
Published: (2023-12-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review
by: Aneta Szudy-Szczyrek, et al.
Published: (2021-06-01)

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
by: Maral DerSarkissian, et al.
Published: (2023-12-01)

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
by: Norbert Grzasko, et al.
Published: (2021-11-01)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
by: Michael Wang, et al.
Published: (2017-11-01)

ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study
by: Hamdy Zawam, et al.
Published: (2018-06-01)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
by: Peng‐Fei Zhang, et al.
Published: (2020-08-01)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
by: Kazuhito Suzuki, et al.
Published: (2023-11-01)

PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report
by: Chenggong Li, et al.
Published: (2021-05-01)

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
by: Jiri Minarik, et al.
Published: (2022-10-01)

Pomalidomide in the management of relapsed/refractory multiple myeloma: A review
by: Sergej Semochkin
Published: (2023-08-01)

Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
by: Cheng Huang, et al.
Published: (2024-01-01)

Modern approaches in relapsed and refractory Hodgkin lymphoma treatment: literature review and own experience
by: Natalia S. Tsaplina, et al.
Published: (2022-11-01)

Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series
by: Chuanwei Yang, et al.
Published: (2022-06-01)

Pretreatment diffusion-weighted imaging for prediction of relapsed and refractory primary central nervous system lymphoma
by: Hsi-Cheng Chien, et al.
Published: (2023-08-01)

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
by: Narendranath Epperla, et al.
Published: (2022-07-01)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
by: Madelyn Burkart, et al.
Published: (2022-03-01)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
by: Jeremy A. Meier, et al.
Published: (2022-02-01)

Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study
by: Tran-Der Tan, et al.
Published: (2020-01-01)

The potential value of ultrasound in predicting local refractory/relapse events in primary thyroid lymphoma patients
by: Jiang Ji, et al.
Published: (2024-03-01)

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
by: Lili Cheng, et al.
Published: (2021-07-01)

Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice
by: Vladimir I. Vorobyev, et al.
Published: (2021-07-01)

Lenalidomide: An Alternative Treatment for Refractory Behçet’s Disease and Relapsing Polychondritis
by: Sofia Gomes Brazao, et al.
Published: (2019-05-01)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
by: Cinzia Pellegrini, et al.
Published: (2016-04-01)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
by: Patrick B. Johnston, et al.
Published: (2018-05-01)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
by: Jeanne Bohler, et al.
Published: (2022-12-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01)

High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma
by: José A. Fernández-Gutiérrez, et al.
Published: (2022-12-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma
by: Catherine S. Y. Lecat, et al.
Published: (2021-07-01)